Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

54 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Eligibility Major Depressive Disorder NCT01035073

- 29/05/17 - 1 modulo, 2 itemgroups, 15 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT01035073

End of Study/Early Withdrawal - CRFs Paliperidone Palmitate Schizophrenia NCT01515423

- 20/09/21 - 1 modulo, 24 itemgroups, 278 elementi, 1 linguaggio
Itemgroups: Date of visit, ECG, Vital signs, Pharmacokinetics, Blood Sample, Paliperidone, Lab Sample Central Lab, Physical Examination, Abnormal Involuntary Movement Scale, Barnes Akathisia Rating Scale, Simpson Angus Rating Scale, Columbia - Suicide Severity Rating Scale (C-SSRS) Since Last Visit Version, Investigator Evaluation of lnjection site, Positive and Negative Syndrome Scale for Schizophrenia, Clinical Global Impression - Severity, Personal and Social Performance Scale, Medication Preference Questionnaire, Involvement Evaluation Questionnaire (Post-Baseline), Resource Use Questionnaire A Hospitalisation, Resource Use Questionnaire B Emergency room visits without hospitalisation, Resource Use Questionnaire C Day clinic, Resource Use Questionnaire D Night clinic, Resource Use Questionnaire E Outpatient treatment, Resource Use Questionnaire F Daily living, Resource Use Questionnaire G Productivity of subject, Evaluation of relapse
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01515423 Sponsor: Janssen Research & Development, LLC Other drug name: TREVICTA®

Visit 8 - CRFs Paliperidone Palmitate Schizophrenia NCT01515423

- 20/09/21 - 1 modulo, 28 itemgroups, 277 elementi, 1 linguaggio
Itemgroups: Date of visit, Randomization, ECG, Vital signs, Pharmacokinetics, Blood Sample, Paliperidone, Lab Sample Central Lab, Urine Dipstick Pregnancy Test, Physical Examination, Abnormal Involuntary Movement Scale, Barnes Akathisia Rating Scale, Simpson Angus Rating Scale, Columbia - Suicide Severity Rating Scale (C-SSRS) Since Last Visit Version, Investigator Evaluation of lnjection site, Subject Evaluation of lnjection site, Positive and Negative Syndrome Scale for Schizophrenia, Clinical Global Impression - Severity, Personal and Social Performance Scale, Administration of trial medication, Medication Preference Questionnaire, Involvement Evaluation Questionnaire (Post-Baseline), Resource Use Questionnaire A Hospitalisation, Resource Use Questionnaire B Emergency room visits without hospitalisation, Resource Use Questionnaire C Day clinic, Resource Use Questionnaire D Night clinic, Resource Use Questionnaire E Outpatient treatment, Resource Use Questionnaire F Daily living, Resource Use Questionnaire G Productivity of subject, Medication Kit Dispensation
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01515423 Sponsor: Janssen Research & Development, LLC Other drug name: TREVICTA®

Eligibility Schizophrenia NCT00686140

- 20/09/21 - 1 modulo, 2 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00686140

Eligibility Treatment-resistant Schizophrenia NCT01105481

- 11/06/17 - 1 modulo, 2 itemgroups, 9 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01105481

Eligibility Schizophrenia NCT00791713

- 11/06/17 - 1 modulo, 2 itemgroups, 14 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER; ODM derived from: https://clinicaltrials.gov/show/NCT00791713

Eligibility Schizophrenia NCT00791167

- 11/06/17 - 1 modulo, 2 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of the Dose Proportionality of Extended Release Paliperidone; ODM derived from: https://clinicaltrials.gov/show/NCT00791167

Eligibility Schizophrenia NCT00538070

- 11/06/17 - 1 modulo, 2 itemgroups, 14 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00538070

Eligibility Schizophrenia NCT00611806

- 11/06/17 - 1 modulo, 2 itemgroups, 17 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00611806

Eligibility Schizophrenia NCT00535132

- 10/06/17 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone; ODM derived from: https://clinicaltrials.gov/show/NCT00535132

Subject level - CRFs Paliperidone Palmitate Schizophrenia NCT01515423

- 28/05/17 - 1 modulo, 12 itemgroups, 95 elementi, 1 linguaggio
Itemgroups: DNA Sample, DNA Sample Consent Modification, DNA Sample Replacement, Dermatology Referral, Early withdrawal from Open-Label Phase, End of Double-Blind Phase/Early withdrawal, Adverse Events, Concomitant Therapy, Comments, Relapse, DSM-5 Diagnosis, Subject Identification
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01515423 Sponsor: Janssen Research & Development, LLC Other drug name: TREVICTA®

Confirmation Visit - CRFs Paliperidone Palmitate Schizophrenia NCT01515423

- 24/05/17 - 1 modulo, 3 itemgroups, 49 elementi, 1 linguaggio
Itemgroups: Date of visit, Positive and Negative Syndrome Scale for Schizophrenia, Evaluation of relapse
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01515423 Sponsor: Janssen Research & Development, LLC Other drug name: TREVICTA®

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial